DANIEL BECK: Open Payments
NPI 1992287544 · SIKESTON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$19,212 in 39 payments from 10 companies in 2025. Trend: 2023 $41,215 · 2024 $25,249 · 2025 $19,212
Speaker / faculty: $16,720Travel & lodging: $1,711Food & beverage: $781
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 25 | $18,929 |
| Alkermes, Inc. | 4 | $74 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| E.R. Squibb & Sons, L.L.C. | 1 | $29 |
| Neurocrine BioSciences, Inc. | 1 | $22 |
| Novo Nordisk Inc | 1 | $19 |
| ABBVIE INC. | 1 | $19 |
| Lundbeck LLC | 1 | $19 |
| AstraZeneca Pharmaceuticals LP | 1 | $16 |
Products named: INVEGA SUSTENNA, ARISTADA, REXULTI, FANAPT, COBENFY, INGREZZA, Wegovy, VRAYLAR.
Industry payments across MO — which companies pay providers there.
